




Searching News Database: adeno-associated virus
HSMN NewsFeed - 10 Sep 2024
Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial Officer
Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial Officer
HSMN NewsFeed - 10 Nov 2023
EU Approval of AAV5 DetectCDx(TM) Provides Access to Companion Diagnostic for Hemophilia A Gene Therapy
EU Approval of AAV5 DetectCDx(TM) Provides Access to Companion Diagnostic for Hemophilia A Gene Therapy
HSMN NewsFeed - 8 Jun 2023
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430
HSMN NewsFeed - 17 Nov 2022
Upstaza(TM) Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
Upstaza(TM) Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
HSMN NewsFeed - 20 May 2022
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
HSMN NewsFeed - 18 Oct 2021
NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
HSMN NewsFeed - 30 Aug 2021
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
HSMN NewsFeed - 18 Jun 2021
Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
HSMN NewsFeed - 2 Nov 2020
Corlieve Therapeutics SAS Closes Seed Financing to Develop Therapies for Severe Neurological Conditions
Corlieve Therapeutics SAS Closes Seed Financing to Develop Therapies for Severe Neurological Conditions
HSMN NewsFeed - 11 Aug 2020
StrideBio Expands Leadership Team with Appointment of William Monteith as Chief Operating Officer
StrideBio Expands Leadership Team with Appointment of William Monteith as Chief Operating Officer
HSMN NewsFeed - 1 Jun 2020
SwanBio Therapeutics Appoints Steven Zelenkofske, DO, as Chief Medical Officer
SwanBio Therapeutics Appoints Steven Zelenkofske, DO, as Chief Medical Officer
HSMN NewsFeed - 15 Apr 2019
Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
HSMN NewsFeed - 30 Aug 2018
REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease
REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease
HSMN NewsFeed - 2 Apr 2018
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
HSMN NewsFeed - 29 Jun 2017
Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals
Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals
HSMN NewsFeed - 6 Jun 2016
Homology Medicines Appoints James Warren, Ph.D. as Vice President of Manufacturing
Homology Medicines Appoints James Warren, Ph.D. as Vice President of Manufacturing
HSMN NewsFeed - 3 Sep 2014
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
HSMN NewsFeed - 23 Jun 2014
Bayer HealthCare and Dimension Therapeutics to Develop Novel Gene Therapy for Hemophilia A
Bayer HealthCare and Dimension Therapeutics to Develop Novel Gene Therapy for Hemophilia A
HSMN NewsFeed - 15 Apr 2014
AAVLife Raises $12 Million in Series A Financing to Advance Gene Therapy for Friedreich’s Ataxia
AAVLife Raises $12 Million in Series A Financing to Advance Gene Therapy for Friedreich’s Ataxia
HSMN NewsFeed - 24 Jun 2011
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
HSMN NewsFeed - 2 Dec 2008
Targeted Genetics Realigns Product Development Priorities and Implements Cost Reduction Measures
Targeted Genetics Realigns Product Development Priorities and Implements Cost Reduction Measures
HSMN NewsFeed - 10 Nov 2008
Targeted Genetics Board of Directors Names B.G. Susan Robinson as President and CEO
Targeted Genetics Board of Directors Names B.G. Susan Robinson as President and CEO
HSMN NewsFeed - 17 May 2007
Celladon and Targeted Genetics Initiate Phase I Clinical Trial of MYDICAR(TM) in Patients With Heart Failure
Celladon and Targeted Genetics Initiate Phase I Clinical Trial of MYDICAR(TM) in Patients With Heart Failure
HSMN NewsFeed - 13 Apr 2007
Ceregene Enrolling Patients for Phase 2 Clinical Trial of Parkinson's Disease
Ceregene Enrolling Patients for Phase 2 Clinical Trial of Parkinson's Disease
HSMN NewsFeed - 27 Feb 2007
Targeted Genetics Responds to Litigation Release SEC V. Crestview Capital Partners, LLC and Stewart R. Flink
Targeted Genetics Responds to Litigation Release SEC V. Crestview Capital Partners, LLC and Stewart R. Flink
Additional items found! 8

Members Archive contains
8 additional stories matching:
adeno-associated virus
(Password required)
adeno-associated virus
(Password required)